Could This Drug Help Ionis Stock Recover From a Disappointing 2016?

Mid cap biotech Ionis Pharmaceuticals NASDAQ IONS announced results from a pivotal trial for an intriguing rare disease drug on March 6 and the market promptly dinged the stock 14 in the next two days over safety concerns But here s the kicker the results are actually